Skip to search formSkip to main contentSkip to account menu

apaziquone

Known as: 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2- ((1E)-3-hydroxy-1-propenyl)-1-methyl-, 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione) prop-beta-en-alpha-ol, 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)prop-beta-en-alpha-ol 
An indolequinone bioreductive prodrug and analog of mitomycin C with potential antineoplastic and radiosensitization activities. Apaziquone is… 
National Institutes of Health

Related topics

Related topics

8 relations

Broader (3)

Antineoplastic AgentsAziridinesIndolequinones

Narrower (4)

E09EO 9EoquinNSC 382,459
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
The efficacy of Apaziquone in the treatment of bladder cancer
ABSTRACT Introduction: Bladder cancer is nowadays a common tumor. Non-muscle invasive bladder cancer (NMIBC) has still chances of… 
Review
2012
Review
2012
Apaziquone as an intravesical therapeutic agent for urothelial non-muscle-invasive bladder cancer
Introduction: Urothelial carcinoma of the bladder is a disease prone to recurrence. A new cytotoxic drug, apaziquone, is an… 
Review
2010
Review
2010
Marker lesion experiments in bladder cancer--what have we learned?
Review
2010
Review
2010
New therapies for non-muscle-invasive bladder cancer
The treatment of non-muscle-invasive bladder cancer (NMIBC) remains a challenge owing to its increased tendency to recur and the… 
Review
2008
Review
2008
Apaziquone for non-muscle invasive bladder cancer: a critical review
Objective: To describe clinical needs in non-muscle invasive bladder cancer (NMIBC) and review the potential of apaziquone in… 
Review
2008
Review
2008
Apaziquone for non-muscle invasive bladder cancer: a critical review.
OBJECTIVE To describe clinical needs in non-muscle invasive bladder cancer (NMIBC) and review the potential of apaziquone in this… 
Review
2007
Review
2007
Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer
Purpose of review Nonmuscle invasive bladder cancer is a common malignancy, usually treated by transurethral resection and… 
2007
2007
Will a new intravesical chemotherapy agent improve the treatment of non-muscle-invasive bladder cancer?
Will a new intravesical chemotherapy agent improve the treatment of non-muscle-invasive bladder cancer? 
2006
2006
Quantitative analysis of EO9 (apaziquone) and its metabolite EO5a in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray tandem mass spectrometry.
A sensitive and specific LC-MS/MS assay for the quantitative determination of EO9 and its metabolite EO5a is presented. A 200… 
1993
1993
Potentiation of EO9 anti-tumour activity by hydralazine.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)